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Failure is the key to success, each mistake teaches us something. 





Do the difficult things, while they are easy and do the great things, while 
they are small. A journey of a thousand miles must begin with a single step. 





Perception is strong and sight weak. In strategy it is important to see distant things as if 
they were close and to take a distanced view of close things. 
Miyamoto Musashi (1584 – 1645) 

ABSTRACT 
Unravelling the genetic susceptibility to complex autoimmune diseases and 
understanding these pathologies on a mechanistic level are major obstacles to improve 
our possibilities for therapeutic intervention and an increase in the quality of life of 
affected patients. Studies in experimental rodent models, that can be run under stable 
environmental conditions, which itself can be subjected to experimental manipulation, 
and in cohorts of potentially unlimited size, hold significant promise for the 
understanding of genes and pathways involved in complex autoimmune diseases. In 
this thesis, which is based on five scientific manuscripts, we initially investigated the 
influence of the genetic background on the ability to detect three major genetic loci 
(Pia4/Cia12, Pia5/Cia3, Pia7/Cia13) for pristane induced arthritis (PIA) in the rat. We 
also investigated the effect of Pia1, which includes the RT1 region (major 
histocompatibility complex (MHC) in the rat). We could show that the major arthritis 
regulator NCF1 as well as the MHC are silent in certain genetic backgrounds, whereas 
their genetic effect on PIA susceptibility can be detected in other, distinct genetic 
setups, arguing for the importance of genetic interactions between MHC and non-MHC 
genes for PIA development. In the second and third paper, we used a unique approach 
with a heterogeneous stock (HS) derived inbred-outbred mouse cohort that had been 
backcrossed to the arthritis susceptible C57BL10/Q (BQ) mouse strain, in order to map 
clinical phenotypes and the autoantibody response during collagen induced arthritis 
(CIA) development. We defined numerous novel loci and fine mapped already 
described quantitative trait loci (QTL) associated with clinical disease and/or 
autoantibody production providing the to date most comprehensive mapping study in 
CIA. The papers 4 and 5 concern the positional identification of candidate genes for the 
CIA loci Cia21 and Cia22 in the mouse. We propose the costimulatory molecule CD2 
as a female specific genetic risk factor for autommunity in the joint and the central 
nervous system (CNS). We also pinpoint the chitinase like gene Chi3l3, also denoted as 
Ym1, as an important immunomodulator in experimental murine arthritis models based 
on both active immunization with collagen (CII) and passive transfer of arthritogenic 
antibodies. Hopefully, the findings presented in this thesis will have clinical 
implications based on the novel genetic targets, we identified. In addition, our data 
demonstrate the difficulties and pitfalls that are associated with gene identification 
using a hypothesis free positional cloning approach in experimental rodent populations. 
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LIST OF ABBREVIATIONS 
ACPA Anti-citrullinated protein antibody 
APC Antigen presenting cell 
CAIA Collagen antibody induced arthritis 
CD Cluster of differentiation 
CIA Collagen induced arthritis 
CFA Complete Freud’s adjuvant 
CNV Copy number variant 
CTLA-4 Cytotoxic T lymphocyte antigen - 4 
CII Collagen type II 
EAE Experimental autoimmune encephalomyelitis 
GPI Glucose 6 phosphate isomerase 
HLA Human leukocyte antigen 
HS Heterogeneous stock 
IFA Incomplete Freud’s adjuvant 
IFNγ Interferon gamma 
IgG Immunoglobulin G 
IL Interleukin 
LPS Lipopolysaccharide 
MHC Major histocompatibility complex 
MS Multiple sclerosis 
EAE Experimental autoimmune encephalomyelitis 
Ncf Neutrophil cytosolic factor 
QTL Quantitative trait locus 
PTPN22 Protein tyrosine phosphatase non-receptor type 22 
RA Rheumatoid arthritis 
SLE  Systemic lupus erythematosus 
SNP Single nucleotide polymorphism 
TCR T cell receptor 
TH T helper cell 
TLR Toll like receptor 
TNFα Tumor necrosis factor alpha 
T1D Type 1 diabetes 
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THE IMMUNE SYSTEM 
Our body is constantly under exposure of invading pathogens such as bacteria, viruses, 
fungi and large multi-cellular parasites. It is our immune system’s task to defend us 
against these foreign invaders. Generally, our immune defences are divided into two 
distinct, but not mutual exclusive categories, namely the innate and the adaptive 
immune system. The innate immune system contains immediate, first line defence 
mechanisms that prevent pathogens from gaining entry into the host at the contact site 
with the environment (skin barrier and mucous secretion); that lead to the activation 
and production of molecules for disposal or destruction of pathogens [complement 
system, reactive oxygen species (ROS), reactive nitrogen species (RNS)]; and 
expression of receptors that recognize pathogen- (PAMPs) or danger associated 
molecular patterns (DAMPs) subsequently leading to cell activation. Pattern 
recognition receptors were postulated by Charles Janeway in 1989, who inferred that 
prior to clonal expansion of the adaptive immune system, activation by PAMPs 
recognized by receptors with broad substrate specificity are an absolute necessity for 
the efficient mounting of an immune response (pattern recognition model) [1]. Of 
particular importance in this process are Toll like receptors (TLRs) that recognize 
bacterial or viral products and have been initially described in fruit flies and later found 
in all higher organisms including mice and humans [2,3,4]. Additionally, specialized 
phagocytic immune cells that function as antigen presenting cells (APCs), ingest and 
digest pathogens and present fragments as antigens via the MHCII to the adaptive 
immune system [5]. The discoveries of TLRs and the unravelling of their importance 
for the innate immune system as well as the identification of dendritic cells (DCs) that 
act as APCs, were jointly awarded the Nobel Prize in Medicine and Physiology in 
2011. An alternative model, proposed by Polly Matzinger, suggested that innate 
immune cells primarily discriminate disturbances of tissue homeostasis by pathogens, 
through the recognition of DAMPs (danger model) [6]. Very recently, two papers 
indicated CLEC9A (DNGR1) as a receptor for filamentous actin of necrotic cells as the 
first DAMP receptor [7,8]. Activation of the adaptive immune system comprised of B 
and T lymphocytes results in a specific response against the invading pathogen, 
whereby B lymphocytes produce antibodies and constitute the humoral part-, whereas 
T lymphocytes provide either help to B lymphocytes aiding antibody production or 
directly mediate a cytotoxic response constituting the cellular arm of the adaptive 
immune system. Characteristically, both the humoral- and the cellular branch of 
adaptive immunity rely on the ability to recombine variable (V), diversity (D), joining  
(J) gene segments in order to generate their B cell and T cell receptors of potentially 
unlimited specificity using the recombination activating gene (RAG) proteins [9,10]. A 
central aspect for the understanding of the adaptive immune system is the concept of 
clonal selection proposed by Burnet [11]. It states that during its activation in response 
to a pathogen only clones with correct specificity are expanded, leading to the 
production of antibodies that mediate destruction of the respective target. Upon re-
infection with the same pathogen the host mounts a more efficient immune response, as 
the adaptive immune system unlike the innate immune defence, is able to generate long 
lived, persisting cells that mediate immunological memory. 
 
AUTOIMMUNITY 
Autoimmunity is generally referred to as the failure of an organism to maintain 
immunological tolerance to self, which leads to an attack of the host’s own immune 
system against potentially any of its tissues, resulting in their destruction and 
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subsequently loss of function. Autoimmune diseases are generally classified as either 
organ specific [multiple sclerosis (MS), type 1 diabetes (T1D), autoimmune thyroiditis 
(AT), myasthenia gravis (MG)] or systemic, as they lead to manifestations in multiple 
tissues and organs [rheumatoid arthritis (RA), systemic lupus erythematosus (SLE)]. 
The term autoimmunity was derived from the paraphrase “horror autotoxicus” coined 
by German immunologist and Nobel Prize laureate Paul Ehrlich, who falsely assumed 
that autoimmunity as a consequence of self-immunization with an antigen is not 
possible [12]. Reasonable estimates state that approximately up to 5% of the human 
population are affected by an autoimmune disease [13].  
The introduction of the clonal selection theory and the concept of immunological 
tolerance by Burnet and Medawar provided the intellectual framework for our current 
understanding of autoimmunity, as a consequence of the breach of immunological 
tolerance to self. Despite of decades of extensive research, the aetiology of this 
phenomenon is far from being understood. Several genetic as well as environmental 
factors may play a role, but their exact contribution and their complex interplay with 
each other remain to date elusive.  
Interestingly, some autoimmune pathologies were found in the case of a few, rare, 
monogenic diseases with Mendelian inheritance pattern, arising from highly penetrant 
mutations in a single gene that proved to be a key regulator of immunological 
tolerance. As an example serve patients with loss of function mutations in the 
autoimmune regulator gene AIRE that develop autoimmune polyendocrine syndrome 
type 1 (APS) also known as autoimmune polyendocrinopathy candidiasis ectodermal 
dystrophy (APECED), displaying hypothyroidism, adrenal insufficiency, 
hypogonadism and recurrent infections with Candida species [14]. Recent work 
indicated that these patients develop autoantibodies against a cytokine named IL-17, 
implicated to be crucial for host defence against fungal pathogens in mice and humans 
[15,16,17]. Mechanistic studies, using AIRE deficient mice, identified this transcription 
factor as a major regulator of central tolerance in the thymus, where it provides a 
molecular switch for the expression of tissue associated autoantigens in medullary 
thymic epithelial cells (mTECs) [18]. 
Accordingly, a major regulator of peripheral tolerance was defined, when loss of 
function mutations in the FOXP3 gene (forkhead box P3) were found to cause 
immunodysregulation polyendocrinopathy enteropathy X linked syndrome (IPEX) in 
humans, which manifests in lymphadenopathy, T1D, psoriatic or eczemic dermatitis, 
food allergies and autoimmune skin conditions such as alopecia universalis or bullous 
pemphigoid [19,20]. Similar phenotypes were described in mice with a point mutation 
leading to FOXP3 deficiency underlying the IPEX comparable scurfy phenotype [21]. 
In both species loss of FOXP3 leads to a dramatic reduction in numbers and function of 
CD4+ CD25+ T regulatory cells, found to be crucial for the maintenance of peripheral 
tolerance and tissue homeostasis [22,23,24,25].  
Apart from these rare, monogenic, primary immunodeficiency diseases exhibiting a 
strong autoimmune component, autoimmune pathologies are generally considered to be 
complex diseases, with a multitude of genetic and environmental factors interacting to 
govern incidence, severity and clinical outcome of a particular disease. 
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AN INTRODUCTION TO MOUSE GENETICS 
The completion of the mouse and the human genome sequence projects, it became 
apparent that there is a large degree of homology between both species [26,27,28]. The 
mouse genome is contained in 20 chromosomal pairs (19 autosomes; X and Y sex 
chromosomes) and current estimations range from 2.7 to 3.4 billion base pairs for its 
size, which is comparable to the human genome. In the initial draft of the mouse 
genome, it has been estimated that approximately 99% of all mouse genes have a 
homologue in humans, 96% of these genes map to the same syntenic region and 80% of 
the murine genes are 1 to 1 orthologues descending from a common ancestor [28]. The 
Ensembl genome browser release 68 for the Mus musculus genome lists 23140 genes 
(including putative pseudogenes, immunoglobulin and T cell receptor (TCR) genes) 
and an additional 37 genes for the mitochondrial genome. Interestingly, more than 98% 
of the human and the mouse genome do not encode for proteins, and in turn are made 
up by seemingly functionless DNA sequences, for which in the term “junk” DNA has 
been coined by Susumu Ohno in 1972 [29]. These sequences comprise intronic and 
intergenic DNA, often consisting of repetitive sequences, mobile genetic elements 
(transposons, retrotransposons), pseudogenes (pseudo-, retropseudogenes) as well as 
non-coding RNA molecules of different size. Very recent data obtained by the 
ENCODE consortium strongly argued against the notion of the existence of “junk” 
DNA, instead indicating that up to 95% of the genomic sequence are used to initiate 
transcription and gene expression [30].  
Novel gene variants can arise during the process of faulty copying of the DNA 
molecule during cell division, whereby many changes affecting the DNA sequence are 
minor point mutations of single nucleotides that lead to the formation of single 
nucleotide polymorphisms (SNPs). SNPs may alter codons, coding for critical amino 
acids of a protein resulting in gain- or loss of function mutations that account for 
differences in genetic susceptibility to complex autoimmune- and/or chronic 
inflammatory conditions. This is illustrated by a naturally occurring SNP in codon 153 
of the neutrophil cytosolic factor (Ncf1) gene in rats that affects ROS production by the 
NADPH oxidase complex (NOX2) and was proven not only to alter susceptibility to 
autoimmune disease, but also to be causal for differences in psychosocial stress 
behaviour in the laboratory rat providing an example for pleiotropy [31,32,33].  
Concordantly, an A to C transversion mutation at the -2 position of the 5’ end of exon 8 
in the Ncf1 gene that spontaneously occurred in a colony of C57BL6/J-m (lpr(db/db)) 
mice, altered a splice site and led to functional deficiency of NOX2 and increased 
autoimmunity [34,35]. A non-synonymous coding SNP encoding for structural 
polymorphism Asp105Gly in the Nramp1 gene leads to increased susceptibility to 
insulin dependent diabetes in NOD mice and prove to be the causative gene for the 
Idd5.2 locus, elegantly shown by in vivo RNA interference by Kissler and colleagues 
[36,37]. This loss of function polymorphism in the phagosomal ion transporter 
NRAMP1 also associated with decreased susceptibility to infection with intracellular 
pathogens like Salmonella typhimurium, Leishmania donovani and certain 
Mycobacterium species [38,39]. An additional example of differential expression of 
alternatively spliced transcripts that mediate the loss of humoral tolerance to nuclear 
antigens, is the identification of the Ly108 gene as part of the murine lupus 
susceptibility locus Sle1b [40,41,42]. This gene is encoded in the SLAM/CD2 gene 
cluster on murine chromosome 1 and implicated to alter the threshold of T cell 
activation and NKT cell numbers [40,43].  
As only few coding or splice site mutations were unambiguously positionally cloned, 
speculation arose that these variations may not be sufficient to primarily account for 
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genetic differences in quantitative phenotypes. In turn polymorphisms affecting 
promoter, silencer, enhancer elements or transcription factor binding sites that influence 
gene expression were suggested to underlie differences in heritability of complex traits 
[44]. This notion poses a significant obstacle for definitive identification of 
polymorphisms underlying QTLs defined by linkage, as it is much more difficult to 
assess functional consequences of a certain associated SNP on the development of an 
expression QTLs (eQTL), which may not be as apparent as for coding- or splice site 
mutations. This problem received increasing attention as large association studies in 
humans often produce strongest hits in gene deserts and non-coding regions of the 
genome [45].  
Other polymorphisms that may underlie complex traits are minor structural alterations 
of the genome leading to insertion or deletion (INDEL) of few nucleotides. These 
alterations have historically been used in mapping studies as they produce micro- or 
macrosatellite markers that can be resolved by gel electrophoresis after PCR 
amplification. Examples, for which INDELs were implicated in genetic susceptibility 
to complex immunological traits, include a 2 bp deletion at positions 62 and 63 of an 83 
base pair exon near the 5' end of the Hc (C5) gene leading to a premature stop codon 
and a truncated protein [46]. This mutation is found in the following mouse strains: 
A/HeJ, AKR/J, DBA/2J, NZB/B1NJ, SWR/J, B10.D2/oSnJ and renders these mice 
susceptible to ovalbumin (OVA) induced allergic asthma [47]. Other minor structural 
variants in a candidate gene for murine SLE like autoimmunity present in multiple 
mouse strains (NZB/BlNJ, BXSB/MpJ, MRL/MpJ, NOD/ShiLtJ, 129S1/SvlmJ, 
NZW/LacJ, SJL/J and SWR/J) are deletions in the promoter and the third intron of the 
Fcgr2b gene, the sole murine inhibitory Fc receptor, expressed on B cells and 
macrophages [48,49,50,51]. In addition, coding non-synonymous polymorphisms, 
found in this gene, form two distinct haplotypes in the laboratory mouse (Ly17.1/2) 
[52]. Though these SNPs lead to amino acid alterations in the extracellular D2 domain 
that interacts with the CH2 domain of the IgG Fc region, there is no evidence of a 
functional impact of these coding variants [53,54]. 
Large genomic alterations involving insertions, deletions, inversions or translocations 
of big stretches of DNA sequence have been described and are increasingly appreciated 
in complex genetics. In mice, a translocation and duplication of the Tlr7 gene locus 
from the X to the Y sex chromosome was found to increase B cell reactivity and 
autoantibody formation manifesting in a systemic lupus erythematosus (SLE) like 
syndrome in Yaa males (Y autoimmune accelerator) [55,56]. Additional evidence for 
the causal role of this mutation was obtained, when the autoimmune phenotype was 
recapitulated by transgenic overexpression of the Tlr7 gene [57,58]. However, other 
genes, included in the translocated DNA segment, may also contribute to increased 
lupus susceptibility [59]. In addition, a copy number variant (CNV) of Fcgr3b gene 
was described to underlie increased susceptibility to glomerulonephritis and SLE across 
species in both rats and humans [60,61]. These and other examples illustrate the 
importance of CNVs as a driving force for genome evolution and genetic susceptibility 
to complex traits [62]. During the last couple of years several research groups 
investigated the global distribution of copy number polymorphisms across the mouse 
genome by massive parallel sequencing of multiple mouse strains [63,64,65]. Thereby, 
the chitinase like gene locus on murine chromosome 3 was implicated to harbour a 
CNV, resulting in a duplication in the 129P2/OlaHsd, 129S1/SvlmJ, NOD/ShiLtJ, 
LP/J, FVB/NJ, CAST/EiJ, C57BL/6NJ mice [66]. This relates to work presented in 
paper 5, where we positionally identified the murine chitinase like gene Chi3l3 as a 
candidate for the control of experimental arthritis in mice.  
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A SHORT GENEALOGY OF THE LABORATORY MOUSE 
Of the > 500 inbred mouse strains and substrains currently used in biomedical research 
are hybrids between the musculus and domesticus subspecies of the house mouse Mus 
musculus. Per definition, a mouse strain is considered to be inbred, when it has been 
repeatedly brother sister mated for more than twenty consecutive generations. Under 
the assumption that no genetic drift occurs, all mice are at this stage genetically 
identical (isogenic) and can be traced back to a single ancestral breeding pair. The 
currently used inbred mouse strains were derived from “fancy” mice maintained as pets 
and initially caught at the beginning of the 19th century. Clarence Cook Little bred the 
first laboratory mouse strain by successive brother sister mating of an initial breeding 
pair carrying the recessive genes for diluted, brown and non-agouti (DBA) [67,68]. The 
most commonly used mouse strain in biomedical research are C57 black derived 
strains, initially derived by Little at the Cold Spring Harbor Laboratories from a 
breeding pair he received from Miss Abbie Lathrop. With the completion of the mouse 
genome project significant hopes were attained to unravel novel gene functions in a 
complex model system and thereby gain a better understanding of the genetic basis of 
pathological situations in humans [28]. 
 
FORWARD VERSUS REVERSE GENETICS 
Identification of genes and pathways controlling quantitative phenotypes are of major 
interest and can potentially be achieved in two distinct not mutual exclusive ways in the 
laboratory mouse. Firstly, a reverse genetic approach is gene centered, hypothesis 
driven, often involving the introduction of an artificial mutation in the gene of interest, 
which in turn is then evaluated for its capacity to influence a particular phenotype [69]. 
Alternatively, for a forward genetic approach novel gene variants can be introduced by 
de novo mutagenesis with N-ethyl-N-nitrosourea (ENU) [70]. Genetic susceptibility to 
autoimmune disease was studied using ENU mutagenesis in mice and led to the 
identification of a loss of function mutation of Rc3h1 (roquin), a posttranscriptional 
repressor of the inducible T cell co-stimulator (ICOS) that mediates the accumulation 
of follicular helper T cells and subsequently anti-DNA antibody formation culminating 
in a lupus like disease [71,72]. Moreover, this phenotype is accompanied by decreased 
susceptibility to Salmonella typhimurium infection [73].  
On the other hand mapping of disease genes in animal models can be achieved in 
hypothesis free manner by the identification of naturally occurring gene variants with 
varying effect sizes, as large cohorts of experimental animals of phenotypic distinct 
inbred mouse strains are available. Initially, identification of quantitative trait loci for a 
particular phenotype is carried out by a correlation of genetic markers with the 
phenotype in a segregating population, defined as genetic linkage analysis. Following 
the identification of the locus, one then isolates the respective region in a congenic 
strain, and tries to narrow down the critical interval that is associated with a particular 
phenotype by recombination assisted breeding. Once the critical interval is sufficiently 
small, one aims to positionally identify candidate genes and polymorphisms that may 
explain the observed phenotype, which in the last step need to be functionally proven to 
firmly establish a quantitative trait gene for a particular QTL. 
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Genome wide mapping strategies 
Following a hallmark paper by Lander and Botstein in 1989 genome wide studies on 
complex phenotypes in experimental rodent populations were performed using F2 
intercrosses or N2 backcrosses [74]. For these, two phenotypically distinct inbred 
strains are intercrossed to produce an initial F1 cohort, of which all individuals are 
genetically identical. Depending on the type of cross these individuals are either further 
backcrossed to one of the background strains or they are subsequently intercrossed to 
accumulate recombinations of parental genetic information. A typical F2 cohort of 
mice consists of several hundreds of individuals that are genotyped on genome wide 
level with molecular markers spanning evenly over the complete genome followed by 
genetic linkage analysis. Bateson and Punnett initially introduced the concept of genetic 
linkage that is defined as the tendency of genes that are located in close proximity on a 
chromosome to be inherited together during meiosis, as the chance of a crossing over 
between chromatids that separate two distinct loci decreases with physical proximity 
[75]. In following, Morgan developed the idea that the amount of recombinations 
observed in a genetic cross could be used for the construction of linkage maps, which 
laid the foundation of modern genetic analysis [76]. Consequently, in any experimental 
cross, genetic markers and genes regulating the phenotype of interest that are in close 
proximity, are very likely to be co-inherited in a filial generation.  
A genome scan using an F2 population usually yields a mapping resolution of 10 to 30 
cM with chromosomal intervals that typically contain hundreds of genes. To date 
approximately 50 QTLs for CIA have been described using these methods, many of 
which overlap with QTLs for other arthritis models as well as other autoimmune 
models like experimental induced autoimmune encephalomyelitis (EAE), clearly 
indicating a common genetic component governing susceptibility to these pathologies 
in the mouse [77,78]. However, the low amount of recombinations that occurs in a F2 
or N2 population strongly impedes with the mapping resolution that can be obtained 
with these conventional methods. Therefore, only for a fraction of QTLs a candidate 
gene or polymorphism has been proposed outlining the difficulties of positional 
cloning. This led to several attempts to increase mapping resolution and subsequently 
facilitate gene identification accounting for differences in heritability of quantitative 
traits in experimental rodent populations. 
 
Advanced intercross lines (AIL) 
To overcome the problem that only few recombination events occur during the 
production of an F2 or N2 filial generation, AILs were initially created. They are 
produced from a F2 population that is randomly intercrossed to acquire recombinations 
between two given loci during the additional filial generations [79]. AILs were used for 
genome wide mapping as well as fine mapping of already existing loci and proof of 
concept has been obtained in numerous studies. Yu and colleagues used a (DBA/1 x 
FVB/N)F11/12 AIL to fine map several CIA loci previously identified in a 
conventional F2 cross [80,81,82]. Another example for successful fine mapping of 
already existing QTLs that laid the foundation for the work presented in this thesis are 
studies done on the Eae2/Eae3/Cia5 susceptibility loci identified in a B10.RIII x 
RIIIS/J F2 population [83,84]. Using a partial advanced intercross (PAI) between 
Eae3/Cia5 and Eae2 bicongenic mice, taking advantage of genetic interactions between 
these loci, led to the identification of several subloci on murine chromosome 3 (Cia5, 
Cia21, Cia22) and chromosome 15 (Cia30, Cia31, Cia32) that interact in complex 
fashion and affect clinical CIA as well as inflammation related cellular subphenotypes 
like alterations in CD4/CD8 T cell populations [85,86]. 
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Heterogeneous stocks (HS) 
An additional resource for fine mapping of QTLs that received increasing attention 
during the last years are HS that are available for both Mus musculus and Rattus 
norvegicus. These stocks are advanced intercrosses with contributions of eight inbred 
strains that have been semi-randomly bred for a multitude of generations. Currently, 
two eight allele heterogeneous mouse stocks are available; the Boulder stock bred for 
more than 60 generations (HSIBG) comprised of (A/J, AKR, BALB/C, C3H, C57BL/6, 
DBA/2, Is/Bi and RIII) and the Northport stock bred for more than 55 generations 
(HSNPT) comprised of (A/J, AKR/J, BALB/CJ, LP/J CBA/2J, C3H/HeJ, C57BL/6J 
and DBA/2J) both originally intended to be used for studies of aging related and 
behavioural phenotypes [87,88]. Of particular importance for this thesis is the HSNPT 
that has been used to create an arthritis susceptible HS derived mouse inbred outbred 
cohort by backcrossing it to C57BL/10.Q (BQ) in a F3 cross (HSxBQ), as HSNPT 
mice itself are resistant to CIA, but not CAIA or EAE induction [89]. The usefulness of 
HSNPT mice for fine mapping of known QTLs was successfully demonstrated by 
studies undertaken by Mott and colleagues [90,91]. These have later been expanded to 
genome wide mapping of a variety of biochemical, immunological, haematological and 
metabolic quantitative phenotypes [92]. In parallel to our own study involving the 
genome wide mapping of CIA in HSxBQ mice presented in paper 2, Johnsen et al. 
utilized the available HSNPT mice to map arthritis severity in an arthritis model 
involving passive transfer of arthritogenic antibodies [93]. While HS mouse cohorts are 
readily available to researchers making tedious work of intercrossing to obtain an 
outbred cohort obsolete, caveats for its use are apparent. Firstly, the number of markers 
that has to be genotyped in these cohorts is very high, as linkage disequilibrium (LD) 
blocks are considerably small due to high amount of recombinations acquired during 
HS construction. Secondly, the cohort size in a single experiment to detect linkage for 
small and intermediate effect QTLs is big as both the number of segregating alleles and 
their interactions with the background genome are usually underestimated by 
bioinformatic methods used for analysis [94]. Lastly, family effects need to be 
corrected in the statistical analysis in order to minimize the amount of false positive 
identified QTLs in a particular cross [94,95].  
 
Collaborative cross (CC) and recombinant inbred lines (RILs) 
The most recent tool for quantitative trait mapping in rodents, are RILs derived from 
the CC experiment, aiming to generate hundreds of RILs from an octo parental cross 
[96]. A RIL is created by repeated intercrossing of two (or more) inbred mouse strains 
until complete fixation of the genome has been achieved. The idea has initially been 
proposed almost ten years ago by the Complex Trait Consortium, yet the CC is still not 
fully available due to the extensive amount of time that is required for the generation of 
the RILs. The major advantage of the CC approach compared to a conventional HS is 
the fact that its RILs have only to be genotyped once and with the complete genotyping 
information available, can be used to map genetic control of multiple phenotypes. 
Furthermore, F1 progeny of RILs from the CC can potentially be created in limitless 
fashion through intercrossing and subsequently be used for mapping projects, 
attempting to model the genetic complexity in humans using genetically normal 
individuals without artificially introduced mutations [97]. The CC was constructed to 
maximally increase the diversity by the inclusion of wild derived inbred mouse strains 
derived from both musculus and castanaeus subspecies, with allele contributions of the 
(129Sv/Im, A, C57BL/6, CAST/Ei, NOD/Lt, NZO/HILt, PWK/Ph and WSB/Ei) strains 
[88]. Very recently, the CC came into focus, as a series of proof of concept studies for 
genome mapping of different quantitative traits using the first CC derived RILs were 
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reported, including a study investigating host resistance to Aspergillus fumigatus 
infection as an immunological phenotype [98]. 
 
Locus based strategies 
Congenic and consomic strains 
In order to achieve positional cloning of genes in using the outlined hypothesis free 
forward genetic approach, it is often necessary to isolate the respective chromosomal 
region implicated in a segregating cross to make a congenic strain. In theory, congenic 
animals are isogenic clones that differ only for the congenic locus from the respective 
background strain. In experimental rodent populations congenics can be produced by 
classical serial backcrossing to the background strain for more than ten generations. 
Alternatively, they can also be obtained by so called “speed congenic approach”, for 
which not only the presence of a desired locus, but also the absence of disturbing donor 
alleles is assessed [99]. Furthermore, consomic mouse strains, in which whole 
chromosomes of inbred mouse strains were substituted, may provide a shortcut for the 
construction of congenic strains circumventing tedious backcrossing [100]. A 
disadvantage for the widespread use of consomic strains is the limited amount of 
chromosomal substitution strains and strain combinations that are available to the 
research community.  
It is of utterly importance to keep in mind that most of the currently used knock out 
strains, which have been made in mixed chimeric backgrounds, are in fact congenic 
strains. During the generation of a targeted mutation in 129 embryonic stem cell lines, a 
129 derived fragment bearing “flanking genes” is carried along, if experiments are not 
performed in this particular background [101]. That these genetic “impurities” can have 
a great functional impact is illustrated by an increasing amount of literature, outlining 
the importance of the genetic background and “flanking genes” for the correct 
interpretation of experimental results, obtained with gene targeting technologies. 
Several examples in which conflicting results using chimeric knock out mouse strains 
at different stages of backcrossing include the Spp1/Opn (osteopontin) gene and its role 
in joint and CNS autoimmunity as well as the role of IFNγ signalling in the non obese 
diabetic (NOD) mouse model of T1D [102,103,104,105]. With genotyping costs 
dropping, SNP marker panels that are already commercially available may be used to 
accurately assess the genetic purity of congenic and conventional gene targeted mice 
alike. Alternatively, experiments using littermate controls, introduction of targeted 
mutations in the mouse strain of interest using the respective ES cells circumventing 
backcrossing issues or in silico mapping strategies discussed in following may be used 
to overcome the problems associated with “flanking genes” in chimeric knock out 
experiments [101,106]. Noteworthy, all congenic mice that are the basis for the 
experiments presented in this thesis have been rigorously evaluated for genetic 
impurities using a custom made 8k Illumina SNP Chip [107].  
 
In silico mapping and expression QTL analysis 
Advances in genomic technologies displayed by large genotyping and sequencing 
projects of multiple laboratory mouse strains, have created hopes that resolution of 
QTLs can be simplified by utilizing the mosaic structure of the mouse and haplotype 
reconstruction without the de novo construction of segregating crosses. These methods 
are based on the fact that all laboratory strains descended from a few founder mice that 
were initially bred and selected at the beginning of the last century. Some of the 
currently used mouse strains are thereby closely related, exhibited by the amount of 
allelic variants that are shared at certain loci between otherwise distinct strains [108]. 
Under the assumption that a series of markers at distinct loci are always co-inherited, it 
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is theoretically possible to predict a variant segregating in a cross, from the respective 
marker information by reconstruction of founder haplotypes that are identical by 
descent. The usefulness of this approach was illustrated by the identification of 
transcription factor binding sites for Yin Yang 1 (YY1) and serum response factor 
(SRF) governing H2-Eα serum levels [109]. Clearly, these assumptions are directly 
correlated with the amount and the distribution of genotyping information available for 
a particular panel of mouse strains as rare, relatively recently occurred genetic variants 
for example mutations acquired during domestication of different mouse strains, that 
may have strong impact on a particular phenotype, but tend to be underestimated with 
this type of analysis. Simulations, using sequencing data of the HSNPT panel in a 
region harbouring an anxiety QTL on murine chromosome 1, illustrated the limitations 
of this approach indicating a highly complex haplotype structure in the laboratory 
mouse [110]. This led to the suggestion to use complete genome sequencing technology 
for different mouse strains to efficiently map quantitative trait associated genetic 
variation. Large full coverage genome sequencing projects of several commonly used 
strains have recently been reported and it can be expected that these will speed up the 
identification of quantitative trait genes [65].  
Another technology that has been proposed to aid the hypothesis free identification of 
candidate genes in experimental crosses is the analysis of gene expression patterns that 
are associated with the development of a particular phenotype governed by a QTL. The 
rationale behind this notion is fuelled by the assumption that the majority of 
polymorphisms underlying heritable differences of quantitative traits, affect mRNA and 
subsequently protein expression of a particular gene rather than their primary amino 
acid structure or splice sites [44,111]. Successful combination of gene expression 
analysis to improve candidate gene identification in QTL mapping studies, has been 
carried out, none the least for the projects concerning the Cia5/Cia21/Cia22 loci, 
including a genome wide gene expression analysis and a QTL restricted gene 
expression analysis [112]. Likewise, for other arthritis loci, namely Cia2 and Cia3 that 
were identified using a F2 intercross and fine mapped with a DBA/1 x FVB/N AIL, 
global gene expression analysis of central and peripheral lymphoid organs during 
different stages of the disease was used to pinpoint candidate genes for these small and 
intermediate effect QTLs [81,113,114]. 
 
Gene identification criteria – “the burden of proof” 
To resolve a QTL and successfully define a quantitative trait gene additional evidence 
beyond positional identification of a candidate gene is required. Flint and Mott 
illustratively described this fact as the “burden of proof” [115]. Certainly, the most 
elegant way to obtain definitive proof for a certain genetic variant underlying a QTL is 
transgenic complementation, by which one allele can be replaced with another through 
genetic modification. However, in many cases, circumstantial evidence, obtained by 
alternative experimental approaches may be sufficient to fortify one’s claim of 
positional identification of a genetic variant responsible for a complex phenotype. 
Several strategies have been proposed and may be combined depending upon 
feasibility, whereby a list of possible experimental approaches include; the 
identification of polymorphisms controlling gene expression of a particular gene or 
alterations of the primary structure of the protein by amino acid substitutions, proof of 
concept by identification of gene function that is related to a particular trait, functional 
studies using in vitro cell culture systems, where effects of different alleles can be 
assessed or deficiency can be modelled by RNA interference, transgenesis with 
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bacterial, yeast artificial chromosomes or small interfering RNAs acting dominant over 
resident host alleles or leading to suppression of gene expression of the host allele; gene 
targeting and knock out technology, which recapitulate findings in original QTL 
mapping studies, screens of artificially induced mutations of mouse mutant archives 
and their respective impact on a particular phenotype and homology searches and 
comparative genomics as polymorphisms underlying QTLs may be conserved over 
species barriers [115,116].  
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RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is regarded a complex autoimmune disease involving 
chronic inflammation of arthrodial joints, mostly affecting the synovial lining 
eventually leading to pain and discomfort, joint stiffness and further progressing to 
cartilage destruction and bone erosion. It affects approximately 0.5 to 1% of the human 
population worldwide, with its peak onset dating approximately to the fourth decade of 
life [117]. Thereby, gender has a strong influence on RA development illustrated by the 
fact that women have an increased risk of developing the disease [118]. RA is a 
systemic autoimmune disease with extra-articular manifestations that include systemic 
inflammation of the sclera, the pleura of the lung and the pericardium as well as 
anemia, vasculitis and rheumatoid nodule formation. It is considered to be rather a 
complex syndrome than a single disease entity and clinical symptoms as well as disease 
course vary greatly between patients further complicating exact diagnosis. Therefore, 
the American College of Rheumatology  (ACR) listed seven criteria, of which at least 
four have to be fulfilled in order to qualify the diagnosis of RA [119]. The symptoms 
include morning stiffness, arthritis of 3 or more joint areas, arthritis of hand joints, 
symmetric arthritis, rheumatoid nodule formation, serum rheumatoid factor (RF) and 
radiographic changes. With the introduction of novel, highly specific biomarkers for 
RA namely, antibodies against citrullinated protein antigens (ACPA), RA diagnosis 
criteria itself were recently been expanded by the European League against 
Rheumatism (EULAR) and the ACR [120]. 
 
GENETIC HETEROGENEITY 
Despite decades of research the aetiology of RA has yet to be determined. First clues 
that genetic predisposition plays an important role for disease susceptibility has arisen 
from studies investigating the disease prevalence in mono- and dizygotic twins and 
siblings and thereby, it has been estimated that a genetic contribution of approximately 
60% to overall disease susceptibility exists [121,122]. The identification of the first 
genetic factor that was linked to RA development followed the discovery of the MHC 
in the late 60s. Mixed lymphocyte cultures showed that the disease is associated with 
certain MHC alleles, in humans designated human leukocyte antigen (HLA), namely 
HLA-DR4 (HLA-DRB1*04) [123]. Following this initial finding several other HLA-
DRB1 alleles were associated with RA and depending on the study it has been 
estimated that the HLA region accounts for 30 to 50% of the genetic association 
making it by far the strongest factor in RA susceptibility. In the late 80s it was 
anticipated by Gregersen and colleagues that all disease associated alleles share a 
common amino acid motif in the hypervariable region of the HLA-DRß1 chain 
comprising the peptide binding cleft, which led to the formulation of the “shared 
epitope hypothesis”, involving the preferential presentation of arthritogenic peptides 
consequently leading to the loss of immunological tolerance [124]. Though, GWAS 
studies investigating the complex nature of RA genetics consequently yielded highest 
association in the HLA region with the HLA-DRB1 polymorphisms being most 
associated, an ongoing debate persists about the nature of additional effects that could 
explain discrepancies in association of different HLA-DRB1 alleles [125]. Recently, 
Raychaudhuri and colleagues provided new clues with an extensive analysis of the 
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genetic contribution of the HLA associated alleles in human RA cohorts claiming that 
association with amino acid polymorphisms in three HLA proteins (HLA-DRB1, HLA-
B, HLA-DPB1) explains most of the MHC association in ACPA positive RA [126]. 
A major step forward in complex disease genetics and the identification of non-MHC 
loci for RA, was the introduction of affordable genotyping methodology for analysis of 
large patient- and control cohorts using a hypothesis free approach, making association 
studies possible. This led to an explosion of data concerning genetic risk factors not 
only for RA, but also for other complex diseases. One of the strongest associations was 
found to a non-synonymous coding SNP (R620W) in the PTPN22 gene encoding for 
the lymphoid specific phosphatase LYP. This association was initially identified in a 
candidate gene study in a T1D cohort and thereafter confirmed in North American RA 
and SLE cohorts of Caucasian origin [127,128,129]. Initially, the disease-associated 
variant of PTPN22 was described as a gain of function mutant, which was difficult to 
join with the fact that PTPN22 constitutes a major negative regulator of early T cell 
activation via T cell receptor signalling [130]. This led to the hypothesis that the 
disease-associated allele may alter the threshold for negative selection in the thymus 
promoting escape of autoreactive T cells or leads to a decreased activity of T regulatory 
cells in the periphery [131]. Recent data involving the generation of humanized 
transgenic mice expressing, the disease-associated variant indicated that the Lyp620W 
variant is a target for rapid degradation by the cysteine protease calpain leading to 
overall reduced levels of Lyp in lymphocytes. In these mice hyperreactivity in the 
lymphoid and dendritic cell compartment was observed providing a more concise 
explanation for the role of PTPN22 as a negative regulator of TCR signalling and 
susceptibility factor in human autoimmunity [132]. Another gene that was associated 
with RA and SLE utilizing a candidate gene approach is the STAT4 gene, encoding for 
a member of the signal transducer and activator of transcription family of proteins, 
further indicating a role for T cells in disease susceptibility [133]. Following this initial 
observation in Caucasians, it has been found that STAT4 constitutes a genetic risk factor 
for development of SLE across different human populations [134,135,136]. The 
STAT4 protein is part of a signalling cascade downstream of the IL-12 receptor, 
involved in TH1 differentiation facilitating IFNγ production in CD4+ T cells [137,138]. 
A general autoimmunity susceptibility factor that is not only associated with RA, but 
also other autoimmune diseases like T1D is the negative regulator of T cell 
costimulation CTLA-4 (cytotoxic T lymphocyte antigen), further outlining the role of T 
cells in RA pathogenesis [139,140]. An example of a genetic risk factor that has been 
associated in population specific manner is the (peptidyl arginine deiminase) PADI4 
gene. The association has only been found in Asian RA cohorts, whereas no association 
was observed in Caucasians of different geographical origin despite similar allelic 
frequencies of the associated SNP strongly arguing for the presence of additional, yet to 
be defined susceptibility alleles in the Asian population that interact with PADI4 
[141,142,143]. It encodes for an enzyme that catalyses the deimination of arginine to 
citrulline, believed to be an important pathway that leads to the formation of ACPA, 
however clear experimental evidence demonstrating this link is so far lacking. Recent 
studies in HSNPT mice using KBxN serum transfer identified PADI4 as a candidate 
gene determining clinical disease severity in an antibody induced model of arthritis 
[93]. 
Another risk factor for RA that was initially identified by a Swedish- American 
consortium is the TRAF1-C5 locus on human chromosome 9 [144,145]. Interestingly, 
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the C5 pathway has also been implicated as one of the major regulators of different 
experimental arthritis models in mice, and is a major candidate gene for the Cia2 locus 
identified in a NOD x B10.Q cross [146,147,148,149]. Another gene that has been 
associated with susceptibility to systemic autoimmune diseases like RA and SLE in 
Caucasians is the ubiquitin-editing enzyme TNFAIP3/A20, which is located on human 
chromosome 6p23 [150,151,152,153]. Recently, mouse models that involved 
conditional ablation of A20 expression in the myeloid lineage developed spontaneous 
arthritis like syndrome, accompanied by an inflammatory bowel disease (IBD) like 
syndrome [154,155]. Last but not least, with particular importance to this thesis is an 
association that has been found to a SNP close to the CD2 gene, as we identified this 
gene as a major candidate gene for the Cia21 locus in paper 4 [156]. 
 
ENVIRONMENTAL FACTORS 
During the last couple of decades there have been enormous efforts in the 
characterization of environmental factors that initiate RA or influence the course of the 
disease. A brief selection of environmental factors that have been implicated in RA 
susceptibility is presented in following. 
 
Sex hormones 
As previously mentioned gender has a strong influence on disease susceptibility and 
female preponderance of about three women to every man affected by RA aligns with 
data concerning gender effect on other autoimmune diseases, with articular symptoms 
such as SLE [157,158]. Though, sexual dimorphism in autoimmune susceptibility has 
been anticipated for several decades, the exact aetiology of this phenomenon has yet to 
be elucidated. The importance of sex hormones in RA as well as other autoimmune 
diseases is best illustrated by the fact that pregnancy itself characterized by high levels 
of oestrogen and progesterone leads to an alleviation of clinical symptoms first reported 
in case reports by Hench more than 70 years ago [159]. Conversely, female RA patients 
often suffer a relapse within 6 months post partum, when oestrogen and progesterone 
levels drop during the lactation period [160]. Besides gonadal hormone related effects 
on the immune system, sex chromosomal specific effects as well as other pregnancy 
related phenomena like mother fetus MHC disparity may play a role, but are difficult to 
study on a human populational level and with definitive evidence for either of these 
hypotheses lacking, a general consensus on the matter has not been reached [161,162]. 
Studies, which tried to investigate the issue of sexual dimorphism of the immune 
response in humans at baseline, indicated that there are indeed differences in the 
immune response between the sexes. Females compared to males seem to have an 
altered cytokine profile, more biased towards a TH1 response, elevated CD4 cell counts 
and generally a higher antibody response towards vaccination [118,163] 
 
Smoking 
Another major environmental risk factor that has repeatedly been associated with RA is 
smoking. Thereby, both the amount of smoking and the duration of cigarette 
consumption seem to influence RA susceptibility [164]. Epidemiologic studies 
systematically investigating the connection between cigarette smoking and genetic risk 
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factors trying to establish a mechanistic link in the human population found an increase 
in risk for the development of ACPA positive RA in smokers that were positive for the 
shared epitope alleles [165]. This data outlines the notion that smoking triggers specific 
MHC dependent immune reactions possibly through the presentation of altered 
immunogenic peptides that contribute to the breach of tolerance and subsequently the 
development of RA [166]. Interestingly, a coding non-synonymous polymorphism in 
the protein tryrosine phosphatase PTPN22, that has been shown to be associated with 
the development of RA, further increased the risk of developing the disease, in 
conjunction with shared epitope alleles and seropositivity for ACPA [167]. Very 
recently, a citrullinated  α-enolase epitope has been implicated as a specific 
citrullinated autoantigen in a subset of ACPA positive patients that links smoking and 
well established genetic risk factors like the HLA and the PTPN22 risk allele providing 
a candidate for an altered peptide involved in breach of tolerance that may be 
causatively linked to autoimmune reaction preceding RA onset in these patients [168]. 
 
Infections 
So far, studies aiming to associate human RA with a specific infection, proposing a 
certain infectious organism as a bona fide environmental trigger for the disease leading 
to breach of tolerance to self and subsequent autoimmunity, have been unsuccessful. 
Some examples of pathogens that have been suggested to play a role in RA 
susceptibility include bacteria like Mycobacterium tuberculosis, Escherichia coli, 
Proteus mirabilis and Klebsiella pneumoniae as well as viruses like the Epstein Barr 
virus or Cytomegalovirus [169]. Epidemiological studies elucidated that patients with 
long standing RA also have an increased risk of developing periodontal disease [170]. 
The anaerobic, gram-negative bacterium Porphyromonas gingivalis a member of the 
Bacteriodetes phylum that is found in the oral cavity is associated with peridontitis 
[171]. Of note is that Porphyromonas gingivalis is currently the only bacterium known 
to expresses peptidyl arginine deiminase enzymes that are able to citrullinate a wide 
variety of proteins [172]. Interesting in this context is that even non-RA patients with 
history of this infection were in some studies found to have antibodies against 
citrullinated proteins (ACPA) [173]. However, other reports examining a direct 
correlation between ACPA titres and Porphyromonas gingivalis infection in new onset, 
never treated RA patients yielded conflicting results and found no correlation [174]. 
 
CURRENT TREATMENTS 
Similarly to other autoimmune disease entities there is no definitive cure for RA, and 
current therapies rather aim to alleviate its symptoms and reduce pain and discomfort 
caused by the disease. The first class of drugs used for RA treatment is DMARDs 
(disease modifying anti rheumatic agents) like methotrexate and others of lesser 
importance like gold salts, leflunomide, chloroquinine and other anti malarial drugs 
[175]. Another class of drugs used to manage RA is called NSAIDs (non- steroidal 
anti-inflammatory drugs) like aspirin, ibuprofen or diclofenac [175]. At last, the most 
successful agents in terms of efficacy currently available for RA are the so-called 
“biologicals”, which target cytokines or cell surface molecules expressed on 
lymphocytes. Thereby, for antagonistic therapies using monoclonal antibodies or 
soluble receptors directed against pathogenic cytokines like TNFα (etanercept), IL-1 
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(anakinra) and IL-6 (tocilizumab) have been developed and marketed [176]. A 
monoclonal antibody targeting CD20 (rituximab), depleting B cells initially produced 
for treatment of B cell lymphomas has also been successfully introduced into the clinic 
for RA underscoring the pathogenic role of these cells as key players in the 
arthritogenic process [176]. At last, a soluble receptor for CTLA-4 (CTLA-4-Ig, 
abatacept) preventing the binding of B7 family costimulatory molecules on T cells with 
their counterparts CD80 and CD86 on APCs, inhibiting positive T cell costimulation 
has also been approved for RA treatment [176].  
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MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a complex neurologic disease involving chronic 
inflammation of the central nervous system (CNS), leading to progressive 
demyelination of the axons of neurons. It has been initially described by the French 
physician Jean Martin Charcot in 1868 as “sclérose en plaques” detected post mortem 
in histological sections of CNS tissue of MS patients [177]. In Sweden it affects 
approximately 0.2 per cent of the population with increasing risk for MS development 
with northern latitude whereas lower disease prevalence was recorded in developing 
countries in Africa, Asia, South America and the Caribbean [178,179,180]. The typical 
symptoms of MS include balance and motoric disturbances, numbness and paralysis of 
extremities as well as vision and sensory disorders. Similar to RA, there is a sexual 
dimorphism in susceptibility to the disease with a moderate female preponderance of 
two women to every man affected by MS and increasing prevalence of MS in women 
has been described in longitudinal studies in Canada [181,182]. 
 
GENETIC HETEROGENEITY 
In line with what has been observed in RA, there is strong evidence for a heritable 
component governing MS susceptibility, exemplified by increased prevalence of MS in 
twins and first-degree siblings [183,184]. Though, very recently Baranzini and 
coworkers closely investigated genetic, epigenetic and transcriptomic differences of a 
twin pair discordant for MS, for which they found no major alterations that could 
explain the disease discordance [185]. Mixed lymphocyte cultures provided the first 
clues for the identification of the HLA complex as the major genetic risk factor for MS 
in humans [186]. In line with the initial observations, the serotype HLA-DR2 has been 
associated in linkage analysis in a dose dependent manner of MS and homozygosity has 
been reported to increase risk as well as clinical outcome of the disease [187,188]. As 
DR2 constitutes a common serotype, systematic genetic reanalysis of the HLA 
association in humans identified the DRB1*1501 allele as the major genetic risk factor 
for MS development across Northern European high risk- and African populations 
[189,190]. In addition to the class II association, HLA class I alleles have been 
described to influence MS susceptibility, whereby HLA-A*0301 constitutes the major 
risk allele [191]. 
In line with what has already been outlined for RA genetics, GWAS studies in patient 
cohorts and controls provided a major step forward for the identification of non-HLA 
susceptibility factors in MS. Thereby, the receptor for the cytokine IL-7 has been 
pinpointed as an important genetic risk factor for MS development [192,193]. 
Interestingly, the IL-7R has also been a major candidate for Eae2 locus on murine 
chromosome 15, identifying syntenic regions in humans and mice controlling similar 
neurological syndrome [83,194]. Noteworthy, with regard to this thesis is the 
identification of an intronic SNP in the CD58 gene, the human ligand for CD2 encoded 
on chromosome 1, identifying the CD2 costimulatory pathway as a potential target in 
MS susceptibility. Several, independent studies by North American, Swedish and 
Australian groups as well as large international collaborative efforts on MS genetics 
convincingly showed that the SNP rs2300747 within the CD58 gene, is associated with 
increased risk of developing MS [195,196,197,198,199]. Thereby, it seems that the 
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protective allele rs2300747G increases the expression levels of CD58 mRNA in 
lymphoblastic cell lines and peripheral mononuclear cells of MS patients coinciding 
with an enhanced function of certain regulatory T cell subsets in vitro [200]. In 
addition, CD2 costimulation of regulatory T cell subsets revealed decreased 
suppressive activity in patients with MS [201]. A genetic factor, that is also associated 
with MS development, underscoring the role of T cells in disease pathogenesis, is the 
IL-2 receptor alpha chain gene [195,202]. In addition, IL-2Rα has been associated with 
development of T1D, an organ specific autoimmune disease involving destruction of 
insulin producing β cells in pancreatic islets [203].  The exact contribution of the 
different alleles of IL-2Rα to disease susceptibility in T1D and MS is complex [204]. 
Concordantly, the IL2 gene on murine chromosome 3 has been identified as a candidate 




Similarly to RA, factors like gonadal hormones, and smoking in conjunction with 
disease susceptible HLA alleles seem to play a role in MS gene environment 
interactions and were proposed as environmental risk factors for MS development in 
Northern European population [207]. Epidemiologic studies evaluating the risk of 
smoking and use of oral snuff showed that only smoking, but not oral use of moist 
tobacco increase the risk of developing the disease arguing that inhaled non-nicotinic 
compounds triggering lung irritation, but not nicotin itself, constitute a risk factor for 
CNS autoimmunity [208,209]. With respect to these epidemiological findings, new data 
obtained in the EAE model in Lewis rats, might be of importance, which indicated that 
autoaggressive T cell blasts are obliged to migrate via the lung in order to acquire the 
capacity to cross the blood brain barrier, thereby creating a proinflammatory 
environment predisposing for a secondary autoimmune attack [210]. 
 
Infections 
Similar results obtained in epidemiologic studies of RA, a definitive proof of concept 
for one specific environmental trigger in MS leading to breach of immunological 
tolerance and breakdown of the blood brain barrier is so far lacking. However, 
circumstantial evidence suggests that infections may play a role in disease 
susceptibility of MS. In humans, T cells reactive against a myelin basic protein peptide 
(MBP93-105) cross react and get subsequently activated by an artificial peptide that 
shares residues with human herpes virus 6 (HHV6) [211]. On the other hand there is 
evidence in the literature suggesting that systemic infections might increase the risk of 
relapses in ongoing MS [212]. 
 
CURRENT TREATMENTS 
Like RA, in MS corticosteroids are used to manage acute relapses of the disease. 
Secondly, the immunosuppressive agent named mitoxantrone otherwise used for 
chemotherapy of cancer is used to treat certain forms of MS, but its use is limited for 
high cardiotoxicity and risk of acute leukaemia [213]. The sphingosine phosphate 
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receptor antagonist fingolimod is used to reduce relapses and delay disabilities in 
patients with relapsing forms of MS. A recently approved immunomodulator that 
marked a major step forward in MS therapy was the introduction of interferon β 
(IFNβ), which is used in substitution therapy [213]. Also available for MS treatment is 
a non-steroidal, non-interferon, antigen specific therapy with glatiramer acetate, a 
scrambled peptide of four amino acids (Ala, Lys, Glu and Tyr) that are present in 
myelin basic protein (MBP) [213]. A humanized monoclonal antibody directed against 
 α4 integrin (natalizumab) is available in the clinic, but currently only used for 
treatment refractory forms of MS, as there is a risk of developing fatal John 
Cunningham virus (JCV) induced progressive multifocal leukoencephalopathy (PML) 
[213]. A promising humanized monoclonal antibody, which entered phase III clinical 
trials, is daclizumab, which is directed against the α chain of the IL-2R gene (CD25) 
[214]. 
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ANIMAL MODELS 
In order to understand the aetiology of common complex diseases, where onset, 
severity and pathology are determined by interactions of multiple factors, it is 
absolutely necessary to study these diseases on organismal level. However, many 
scientific experiments are for ethical reasons not allowed in humans. Therefore, animal 
models, closely resembling human disease, provide a unique opportunity to identify 
and characterize disease-associated pathways and make therapeutic intervention 
possible. An advantage is that they can be induced by standardized protocols under 
defined environmental conditions with complete control of the genetic setup of the 
investigated model organism. There are numerous animal models for autoimmune 
diseases in rodents, which probably mimic different aspects of the human pathology in 
patient subsets. Naturally, it is absolutely necessary to carefully characterize and 
compare the existing models with regard to human pathology and establish novel ones 
to fully cover the pathogenesis of human disease.  
 
EXPERIMENTAL ARTHRITIS IN RODENTS 
Arthritis models in rodents can grossly be distinguished into two distinct categories. 
Firstly, spontaneous models of arthritis arise from genetic manipulation or spontaneous 
mutation of genes regulating key pathways controlling arthritis susceptibility. In 
contrast, arthritis resembling diseases can also be induced in genetically susceptible 
rodents by immunization with various substances or passive transfer of arthritogenic 
antibodies.  
 
Spontaneous arthritis models 
SKG mutant mouse 
The SKG mouse model of RA has originally been identified by Shimon Sakaguchi’s 
research group as a spontaneous mutation in the Zap70 gene that arose in a colony of 
BALB/C mice [215]. ZAP70 constitutes a key signal transduction molecule in T cells 
and a point mutation altering amino acid 163 from tryptophane to cysteine 
subsequently attenuates TCR signalling, altering T cell selection in the thymus 
promoting the escape of otherwise negatively selected autoreactive, arthritogenic T 
cells [216]. Interestingly, the penetrance of this model is strongly dependent on the 
microbial status of the host, as arthritis is not observed in germ free mice [217]. 
Thereby, yeast derived molecular pattern recognition molecules like β glucans 
(zymosan) and α mannan can trigger or augment joint autoimmunity in SKG mice, 
whereas blockade of Dectin-1, which is one of the major receptors for yeast derived 
molecular patterns suppresses the disease [217,218,219]. The arthropathy in SKG mice 
is cytokine dependent, as arthritis promoting effects for proinflammatory cytokines like 
IL-1, IL-6 and TNFα were observed, whereas IL-10 acts as a strong disease 
suppressant [220]. 
 
Abnormal limb (ALI) mutant mice 
Large phenotypic screens for abnormal limb phenotypes in mice using a forward 
genetic approach with ENU mutagenesis led to the identification of a point mutation, 
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resulting in a gain of function mutant of the phospholipase Cγ2 (Plcg2) gene. These 
mice displayed a severe arthropathy and autoimmunity characterized by B cell 
dependent, but T cell independent, autoantibody production based on hyperreactivity in 
the humoral compartment through excessive calcium entry in B cells [221]. A transient 
expansion of the innate immune cell compartment contributing to progressive joint 
inflammation was also observed [221]. An additional independently identified mutation 
(ALI14) in the Plcg2 gene was shown to promote arthritis and alterations of the 
immune system, but also displayed metabolic and fertility abnormalities [222]. Both 
gain of function mutations seem to compromise the autoinhibition of enzymatic activity 
of PLCG2 accompanied by increased membrane interactions of the protein in this 
hyperactive state [223]. 
 
Ncf1 mutated mouse 
Though NCF1 has originally been identified as an arthritis regulator across rodent 
species in induced models of arthritis, it also promotes a spontaneously occurring 
arthritis like syndrome in ageing mice and post partum in female mice [31,35,224]. 
Recent data indicated that the spontaneous arthritis development might be 
environmentally triggered as Ncf1 mutated and knock out animals are hypersusceptible 
to infection with otherwise commensal Staphylococcus aureus and xylosus species 
[225]. 
 
TNFα transgenic mouse 
Another spontaneous murine model for RA is based on transgenic overexpression of a 
modified human TNFα gene or of a mutated murine transmembrane form of this 
cytokine, resulting in a progressive polyarthritis with 100% penetrance [226,227]. The 
severity of the disease is dependent on the genetic background as DBA/1 mice are most 
susceptible [228]. It is strictly independent of the adaptive arm of immune system as 
neither deficiency in B and T cells nor reciprocal bone marrow reconstitution 
influences the disease development [227,229]. Instead arthritis pathogenesis in TNFα 
transgenics seems to critically depend on synovial fibroblasts [229]. Crucial cytokines 
for arthritis pathogenesis are TNFα and IL-1, but not IL-6, demonstrated by the fact 
that the respective antagonistic treatments or genetically engineered deficiency of the 
first two, but not the latter cytokine, block the development of the disease 
[226,230,231]. 
 
IL-1R knockout mouse 
In the year 2000, Horai and colleagues reported spontaneous arthritis involving 
deficiency in the IL-1R antagonist and in line with previously described models the 
arthropathy in these mice strongly depends on the genetic background outlining the 
importance of genetic interactions [232,233]. The adaptive arm of the immune system 
is critically linked to clinical disease development, indicated by arthritis resistance in 
RAG and TCRα deficient mice and the fact that autoantibodies could be observed 
[232,234]. In line with the genetic data, it was shown that T cell differentiation induced 
via co-stimulatory molecules CD134, CD154 and CD28 play a prominent role for 
disease initiation [234]. Experiments, concerning the cytokine dependency of this 
disease, elucidated the importance of TNFα and T cell derived IL-17, but not IL-6, 
governing the initiation and progression of joint pathology [235,236]. In contrast, 
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TNFα, but not IL-6 or IL-17, seems to be crucial for T cell independent psoriasis like 
disease in these mice [237]. 
 
IL-6R transgenic mouse 
Following identification of the IL-6/IL-6R axis as a crucial player in CIA, a 
spontaneous arthritis model involving the IL-6 receptor was described [231,238,239]. 
These mice bear a single point mutation in the src homology 2 domain-bearing protein 
tyrosine phosphatase (SHP)-2 binding site of gp130, a subunit of the IL-6R receptor, 
mutating tyrosine 759 to phenylalanine, which results in excess activation of STAT3 
and a RA like disease in aging mice [240]. Disease development in these mice was 
dependent on lymphocytes, accompanied by autoantibody production and accumulation 
of myeloid cells and activated T cells that expand under homeostatic conditions in IL-7 
dependent manner [241]. Besides, the proinflammatory cytokine IL-17, exacerbated 
autoimmunity and arthritis in gp130(759F/F) mice, by a positive feedback loop, 
involving IL-6 secretion [242].  
 
KRN transgenic mouse 
An immune complex mediated, spontaneous arthritis was accidently identified, when 
KRN TCR transgenic mice (recognizing the bovine RNase in H2-Ak context) on 
C57Bl6 background were crossed to H2-Ag7 bearing NOD mice (K/BxN) [243]. These 
F1 progeny develop a polyarthritis from 3 weeks of age and autoimmunity in this 
model is directed against the ubiquitously expressed glucose 6 phosphate isomerase 
(GPI) enzyme, which catalyses the second step of the glycolysis following initial 
phosphorylation at the C6 atom, thereby mediating isomerisation of glucose 6 
phosphate to fructose 6 phosphate [244]. Antigen specific T cells in the periphery 
precede the onset of arthritis in these mice, but B cells are also critically required as 
high transient levels of arthritogenic, anti-GPI autoantibodies perpetuate arthritis in 
K/BxN mice [244]. Surprisingly, anti-TNFα treatment at the time of disease onset does 
not block the arthritis development, whereas IL-4 dependency has been indicated as 
reduced disease is observed in the respective knock out mice as well as those 
undergoing anti-IL-4 treatment [245,246]. The importance of loss of tolerance to GPI in 
the arthritogenic process is illustratively shown by the fact that immunization with the 
both human GPI protein (hGPI) and immunodominant peptides induced arthritis like 
disease in genetically susceptible mice [247,248,249]. Despite, the ubiquitous 
expression of the bona fide autoantigen, pathology in these mice is surprisingly limited 
to inflammation to the joint and the heart valve resulting in progressive endocarditis 
[250]. 
 
Induced arthritis models 
Besides spontaneous models, arthritis resembling pathologies can be triggered in rats 
and few mouse strains by intradermal immunization with mineral oil based adjuvants 
like pristane or incomplete Freud’s adjuvant (IFA) as well as long carbon chain 
triterpenes (squalene) or alkanes like (hexadecane). Other forms of arthritis can be 
induced by infection of rodents with Staphylococcus, Mycoplasma and Borrelia as well 
as the passive immunization with their respective cell wall components. Arthritis in 
rodents can also be elicited by immunization with ubiquitously expressed antigens like 
hGPI emulsified in an adjuvant. Immunization with cartilage components, like type IX 
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collagen, aggrecan, cartilage oligomeric protein and proteoglycan in IFA or complete 
Freud’s adjuvant (CFA), stably induces acute and sometimes chronic forms of joint 
inflammation. A model, which was extensively used in this thesis is based on the 
immunization with collagen type II (CII), the major protein component of articular 
cartilage emulsified in a mineral oil based adjuvant, whereas another class of induced 
arthritis models is based on passive transfer of antibodies either by transfer of 
arthritogenic serum or purified monoclonal antibodies. 
 
Pristane induced arthritis (PIA) 
Pristane is a saturated polyisoprenoid alkane (2,6,10,14 tetramethylpentadecane) that 
can be isolated from the liver of sharks [251]. The monosaturated diterpenyl alcohol 
phytol occurring as an ester in chlorophyll is the likely ubiquitous source for pristane in 
nature [252]. Interestingly, phytol has been found to increase oxidative burst in vivo 
and thereby corrected the genetic effect on PIA of a loss of function mutation in Ncf1 
in the dark agouti (DA) rat [253]. A single intradermal injection of pristane induces a 
severe polyarthritis approximately 10 to 14 days after initial immunization in 
genetically susceptible DA rats that shares many macroscopic and histological features 
with human RA [254]. The peak of the acute arthropathy is usually reached after 3 
weeks, and clinical disease subsides thereafter. Eventually, rats will progress into a 
chronic phase of arthritis that may last for several months. Though, the pathological 
mechanisms that govern PIA are far from being understood it has been suggested that T 
cells play a prominent role in susceptibility to the disease. This is illustrated by the fact 
that both depletion of αβ T cells or the TH1 associated proinflammatory cytokines 
TNFα or IFNγ ameliorate clinical disease in preventive and therapeutic treatment 
regimen [254,255]. Additional evidence for the prominent role of T cells in PIA 
pathogenesis stems from the fact the disease can be adoptively transferred using 
adjuvant primed, concavalin A (ConA) restimulated CD4, but not CD8 αβ T cells that 
were isolated from spleen or lymph nodes [255,256]. In line with what has been found 
in PIA, there is a strong dependency for TH1 cytokines secreted by donor CD4 αβ T 
cells, as antagonistic treatment with TNFα or IFNγ neutralizing antibodies in the 
recipients alleviates clinical disease [255].  
Accompanying evidence for the role of T cells and the adaptive immune system in PIA 
arose from various mapping studies using DAxE3 crosses, which consequently yielded 
high association signals in the MHC region on rat chromosome 20 [257,258]. This 
result is somewhat surprising as in PIA as well as in other adjuvant induced arthritis 
models elicited by immunization with squalene, IFA or avridine, no administration of 
an antigen is involved [259]. Blocking experiments with antibodies directed against rat 
MHCII molecules confirmed the notion that adjuvant primed, ConA stimulated T cells 
critically depend on MHCII mediated activation in order to retain their arthritogenic 
potential [255]. Forward genetic studies in the laboratory rat identified an 
aforementioned coding non-synonymous polymorphism in the Ncf1 gene underlying 
the Pia4 susceptibility locus that is believed to govern the development of arthritogenic 
T cells [31].  
Despite several years of research the nature of the postulated autoantigens for PIA still 
remains elusive, though recently the heterogeneous nuclear riboprotein (hnRNP)-A2 as 
well as collagen type XI (CXI) have been proposed as candidates for different phases of 
the disease [260,261]. The autoantigenicity of hnRNPs seems to critically depend on 
the ribonucleic acid component as nuclease treatment abrogates adoptive arthritis 
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transfer with hnRNP restimulated splenocytes [262]. Even though autoantibodies like 
rheumatoid factor (RF) can be found during PIA, it is generally not considered an 
arthritis model that is majorly governed by autoaggressive B cells, as neither transfer of 
serum, nor purified immunoglobulins (Ig) from arthritic rats, do elicit similar disease in 
naïve hosts [254,256]. In paper 1, we have used PIA in order to investigate the 
influence of the genetic background on the ability to detect the strongest described non-
MHC loci in the laboratory rat. 
 
Collagen induced arthritis (CIA) 
With regard to this thesis the most important arthritis model has been CIA. Despite the 
fact that this model can be induced with immunization of autologous collagen (CII) in 
some genetically susceptible rodent strains that are sensitive to arthritis, it is mostly 
elicited by intradermal immunization with heterologous collagen emulsified in CFA or 
IFA [263].  CIA was initially described 35 years ago by Trentham et al. and can be 
elicited across species not only in rodents like rats, mice and guinea pigs, but also in 
non-human primates [264]. During disease development in rodents the initial 
immunization is followed by a severe reactive polyarthritis 3 to 5 weeks, which may 
resolve after three to four months or depending on the genetic background can become 
chronic and even show relapses similar to the human situation. Clinical CIA closely 
resembles human RA, exhibiting erythema, synovial hyperplasia, influx of 
inflammatory cells like macrophages and neutrophils, pannus formation, cartilage 
destruction as well as bone erosions. In line with what has been observed in human RA 
the major genetic factor determining susceptibility to CIA is the MHCII. In mice, H2-q 
and H2-r and possibly H2-b haplotypes confer susceptibility to CIA, induced with 
heterologous collagen emulsified in adjuvant [265,266]. A significant advance for the 
understanding of the aetiology of the disease marked the positional identification of the 
Aβq gene that is responsible for arthritis susceptibility in CIA, whereas mouse strains 
expressing the closely related Aβp gene are completely resistant to arthritis induction 
[267]. Proof of principle has been obtained by transgenic complementation studies that 
altered the critical amino acid in Aβp resembling Aβq, which in turn rendered these 
mice susceptible to CIA induction [268]. One of the possible explanations is a higher 
affinity for the immunodominant T cell epitope of collagen (CII256-270) of Aβq 
compared to Aβp [269]. Rat collagen differs in a single amino acid (Asp266Glu) from 
the mouse peptide (CII256-270), and differences in the affinity between these two 
peptides may explain the increase in arthritis susceptibility after induction of CIA with 
rat compared to mouse CII in H2-q bearing mice [270]. Interestingly, experiments 
using humanized HLA-DR4 expressing transgenic mice identified the glycosylated 
immunodominant epitope CII263-270 that is also recognized in human RA patients 
[271]. Consequently, various humanized transgenic mouse models bearing human 
HLA-DR1, HLA-DR4 and HLA-DQ8 susceptibility display increased CIA 
susceptibility upon CII immunization, whereas transgenics for human resistance MHC 
alleles conferred protection in genetically susceptible mouse strains [272,273,274].  
CIA is generally considered an autoimmune model that depends on the cooperation of 
B and αβ T cells as the respective knock out models proved to be resistant to its 
induction [275,276]. The role of T cells is further outlined by the fact that knock out 
mice for T cell associated costimulatory molecules like CD28 or ICOS are also 
resistant to CIA development [277,278]. In line with this notion, knock out mice 
deficient in murine B cell coreceptors CD19/CD21 also fail to develop CIA, even 
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though they mount comparable antibody responses to heterologous and autologous CII, 
indicating diminished B cell help for autoreactive T cells [279]. The cytokine response 
during CIA has been carefully characterized in numerous studies, which laid the 
foundation for the development of antagonistic cytokine treatment for human RA. 
Neutralization of TNFα using antibodies was shown to reduce joint inflammation and 
cartilage destruction in murine CIA, marking a significant milestone for the 
establishment of anti TNFα therapy [280]. Classically, CIA has been considered a TH1 
type of disease even though therapeutic targeting of the key cytokine INFγ by 
antibodies yielded conflicting results, depending on route of administration and time 
points during disease, when treatment was initiated [281,282,283]. In addition, genetic 
ablation of IFNγ or its receptors resulted in partially opposite phenotypes, and both 
genetic background related effects as well as the protocols used for initiation of CIA 
might have contributed to the discrepancies in the data [284,285,286,287].  
A novel proinflammatory T cell subset, that has been recently discovered and seems to 
play an important role in CIA susceptibility, are TH17 cells illustrated by the fact that 
neutralization of IL-17 as well as the respective knock out mice prove to display 
reduced CIA severity [288,289]. On the other hand TH2 cytokine ablation by the 
aforementioned methods exacerbated disease in case of IL-10, whereas 
supplementation therapy with exogenous recombinant IL-10 ameliorated the disease 
[290,291]. Experiments using both the CIA and the EAE model, evaluating the role of 
the humoral part of adaptive immunity proposed a regulatory role for IL-10 producing 
B cells in these diseases [292,293]. The role of IL-4 in CIA remains controversial with 
probably divergent possibly antagonistic roles for this cytokine during the course of the 
disease [294,295,296].  
Furthermore, B cells as source of autoantibodies are an important player in CIA. A lack 
of negative selection of B cells can be inferred from the robust, specific 
immunoglobulin G (IgG) response directed against CII, which is readily detectable 
prior to disease onset and maintained during CIA development [297]. Moreover, the 
triple helical structure of CII seems to play a crucial role for CIA induction, as 
denatured CII fails to induce a sufficient antibody response to cause CIA [298]. 
 
Collagen antibody induced arthritis (CAIA) 
In CIA, anti-CII antibodies are a driving force in disease pathogenesis, illustrated by the 
fact that passive transfer of anti-CII antibodies from CIA immunised mice into naïve 
hosts elicits a similar disease [299,300]. Markedly, the same results have been obtained 
across species after transfer of anti-CII antibody containing Ig fraction of a RA patient 
into mice [301]. The pathogenic B cell response during CIA development was carefully 
characterized and B cell hybridomas against six major epitopes (M2139-J1, CIIC1-
C1III, UL1-U1, CIIC2-D3, CIIF4-F4, CIIE8-E8) were described, of which some were 
used for transfer experiments presented in paper 4 and 5 [302]. These epitopes are also 
recognized in human RA patients, reacting against modified cartilage, further 
underscoring the relevance of CIA as a relevant model for human RA [303,304]. 
Monoclonal antibodies derived from these hybridomas were carefully characterized for 
their arthritogenicity and found to induce arthritis upon single injection as well as in 
different combinations [305]. Several studies demonstrated that pathogenic antibodies 
against CII alter cartilage ultrastructure leading to loss of fibrillious CII and induce 
chondrocyte death in vitro, probably explaining why antibody transfer alone is able to 
elicit arthritis [306,307]. 
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A few days after initial antibody transfer the disease is usually enhanced with an 
adjuvant like lipopolysaccharide (LPS) boosting the innate immune system leading to 
an acute form of self limiting arthritis, resembling actively induced CIA [302]. Studies, 
undertaken to evaluate the importance of TLRs in this process, yielded that TLR4 
signalling plays a prominent role in mediating LPS induced aggravation of CAIA 
[308]. On the other hand ROS dependent exacerbation of CAIA by LPS seems to rather 
operate via TLR2 [309]. With regard to this thesis the downstream events after 
application of different environmental triggers, the genetic factors involved and their 
consequences for disease pathology are subject of paper number 5. The adaptive 
immune system seems to be dispensable for CAIA illustrated by the fact that the MHC 
region did not exert any influence on CAIA susceptibility and mice deficient in either 
the B or the T cell compartment do not show any significant differences in clinical 
disease [299,302,310]. However, double deficient mice develop less clinical CAIA 
arguing that either component of the adaptive immune system may exert a regulatory 
role in this scenario [310].  
It is generally accepted that the innate arm of the immune system is the major player 
determining the pathogenesis of CAIA. The importance of granulocytic cells such as 
neutrophils is underscored by the fact that mice with genetic deficiencies affecting 
neutrophil numbers as well as treatment with a neutrophil depleting antibody protect 
from CAIA development [302,311]. Of importance, for the induction of CAIA, are Fc 
receptors, initially hypothesized after common γ chain knock out mice have been found 
to be resistant to arthritis induction with anti-CII antibodies [312]. Several studies using 
forward and reverse genetic approaches confirmed that the Fc gene cluster on murine 
chromosome 1 is involved in arthritis susceptibility in both CIA and CAIA 
[149,312,313]. However, the exact contribution of both activating- and the inhibitory 
Fc receptors to autoantibody mediated pathologies in the mouse remain not entirely 
understood, as early studies involving gene targeted mice for particular Fc receptors 
were hampered by the use of genetically impure, chimeric mice, leading to confusion 
within the literature [314,315]. Pathogenic antibodies against CII do not only crosslink 
Fc receptors on immune cells, thereby contributing to joint inflammation, but are also 
able to fix complement, depending on their isotype. The disease modulating effect of 
the complement system in immune complex mediated diseases such as CAIA may 
happen at different levels, for example by promotion of phagocytosis of opsonized 
particles, facilitation of immune complex clearance, lysis of target (host) cells via the 
membrane attack complex and attraction of inflammatory cells with anaphylatoxins 
[316]. 
 
K/BxN serum transfer induced arthritis 
As previously outlined K/BxN transgenic mice, that recognize GPI develop a 
spontaneous arthritis like syndrome, characterized by high titres of anti-GPI antibodies 
of predominantly γ1 isotype. The pathogenicity of these autoantibodies is illustrated by 
the fact that both serum transfer from K/BxN mice as well as transfer of purified anti-
GPI antibodies elicits arthritis in naïve hosts [147]. This disease proved to be largely 
independent of the adaptive immune system as neither the MHC is a susceptibility 
factor, nor are B and T cells an absolute requirement for disease development, based on 
experiments in immunodeficient RAG1 knock out mice [317]. However, a regulatory 
role of proinflammatory TH17 cells was proposed by the Mathis/Benoist group, who 
initially identified this model [318]. An environmental effect on disease susceptibility 
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in this setting cannot be excluded, as microbial colonization of mice with TH17 
promoting segmented filamentous bacteria promotes the disease [319].  
More established is the role of the innate arm of the immune system in the development 
of K/BxN serum transfer arthritis. Both neutrophil- and macrophage depletion with 
anti-GR1 (RB6) antibodies or clodronate liposomes respectively, render mice resistant 
to K/BxN serum induced arthritis, whereas reconstitution experiments in the latter case 
restored the disease susceptibility [320,321,322]. Additional evidence for the role of 
macrophages comes from K/BxN serum induced arthritis resistant osteopetrotic op/op 
mice, which carry a spontaneous nonsense mutation in the Csf1 gene and therefore lack 
cells of the monocyte/macrophage lineage [323,324]. A series of experiments 
suggested the importance of mast cells for disease initiation, as mast cell deficient mice 
with mutations in either Kit or its receptor, prove to be resistant to disease induction, 
which in turn can be broken by mast cell engraftment [325]. However, this notion was 
challenged with the introduction of highly specific CRE mediated ablation of mast cells 
in mice, which did not display altered disease susceptibility upon K/BxN serum transfer 
[326]. Additionally, a disease-modifying role for platelet microparticles has been 
suggested [327].  
On the cytokine level, quintessential roles for IL-1β and TNFα in disease development 
were proposed based on studies in knock out mice for the respective cytokines, their 
receptors as well as conventional QTL mapping and comparative analysis of cytokine 
secretion in different low and high responder mouse strains [328,329,330]. On the other 
hand the cytokines IL-6 and IL-4 prove to be dispensable, as the respective gene 
targeted mice did not show altered disease susceptibility [246,328]. Sequential analysis 
of the events that lead to neutrophil infiltration during K/BxN serum transfer stressed 
the importance of Fc receptor genes, complement factor C5a and neutrophil adhesion 
molecules for the development of this disease [321]. The importance of Fc receptors is 
further outlined by resistance to K/BxN arthritis in knock out mice for the common γ 
chain [331]. Thereby, the activating Fc gamma receptor III seems to play a prominent 
role, whereas reports for the solely inhibitory Fc gamma receptor IIB remain 
controversial [331,332]. Studies with different deficiencies in complement pathways 
outlined the importance of the alternative, but not the classical or lectin binding 
pathway of complement activation, with particular importance for the anaphylatoxin 
C5a for the recruitment of neutrophils [331,333]. A hypothesis free approach mapping 
clinical disease severity of K/BxN serum transfer, using HS mice, confirmed a QTL at 
the Hc gene locus and identified Ptgs1 (Cox1) as a likely candidate gene involved in 
severity of joint disease [93]. 
 
EXPERIMENTAL MULTIPLE SCLEROSIS MODELS 
As for arthritis, animal models for MS can be distinguished into spontaneous and 
induced ones. A distinct category of MS mimicking animal models in rodents is 
mediated by adoptive transfer of pathogenic T cells. In addition there have been 
descriptions of mouse models like quaking viable (qkv) mice that display 
neurodegeneration and dysmyelination, but the phenotype did not appear to be 
lymphocyte dependent [334,335]. 
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Spontaneous multiple sclerosis models 
Spontaneous EAE like disease has been observed in several transgenic mouse strains, 
which bear transgenic TCRs specific for immunodominant epitopes of brain constituent 
proteins like myelin basic protein (MBP) or proteolipid protein (PLP) [336,337,338]. 
However, the spontaneous disease development is clearly linked to the environment, 
since it does not develop in specific pathogen free environment. Thereby, the activation 
state of APCs determined by the exposure to microbial products is critical for initiation 
of CNS pathology in these transgenic mice [339]. Another transgenic mouse line 
bearing a TCR specific for myelin oligodendrocyte glycoprotein (MOG) amino acid 
35-55 peptide spontaneously developed optic neuritis with an incidence of 30%, but did 
not progress to full blown encephalomyelitis like disease [340]. Significant excitement 
arose, when two groups back to back reported the generation of a spontaneous mouse 
model for neurodegenerative disease. As they crossed these MOG35-55 specific TCR 
transgenic mice to transgenic mice bearing Ig heavy chain knock in replacing the J 
region by the recombined heavy chain of a monoclonal antibody binding to a 
conformational epitope on MOG in the context of I-Ab, more than half of these double 
transgenic mice developed distinct inflammatory lesions in the spinal cord and optical 
nerves, but not in the brain, closely resembling Devic disease in humans [341,342]. In 
addition, the development of a distinct MOG specific TCR recognizing peptide 92-106 
in the context of I-As and the previously outlined heavy chain knock in produced a 
spontaneous relapsing remitting EAE like syndrome, when this double transgenic 
mouse line was backcrossed to the SJL/J background [343]. Spontaneous EAE like 
syndrome was also observed with varying incidence in case of a few lines transgenic 
for human HLA-DR2 MS associated alleles in conjunction with transgenic TCRs 
recognizing MBP, axillary molecules facilitating MHC/TCR interaction and in some 
cases mutations preventing receptor rearrangement [344,345,346]. 
 
Multiple sclerosis models based on adoptive cell transfer 
A major difference to CIA induced with articular CII is that EAE can be elicited by 
adoptive transfer of encephalitogenic T cells into naïve hosts. Initially, this model was 
established by transfer of lymph node cells from rats immunized with spinal cord 
homogenate [347]. Later it was shown that it relies on transfer of MHCII restricted T 
cells [348,349]. The most common models involve transfer of CD4+ T cells, however 
transfer of MBP specific CD8+ T cells from shiverer mice, genetically deficient in 
MBP, was also proposed to elicit clinical EAE [350,351]. Similarly, what has been 
found for actively induced EAE, passively transferred disease was initially perceived as 
a TH1 like disease, since cytokine profiling of transferred T cells indicated IFNγ as the 
majorly produced cytokine and the main pathogenic driver CNS pathology [352]. 
However, with the identification of a novel proinflammatory T cell subset, IL-17 
producing TH17 cells, which were also shown to regulate experimental 
neuroinflammation, this concept has been partially reevaluated [353,354,355]. Thereby, 
both the TH1 and TH17 differentiated T cells seem to be encephalitogenic and thereby 
may complement each other in the pathogenic process to facilitate lesion development 
in distinct regions of the CNS [356]. 
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Induced multiple sclerosis models 
The most commonly used animal model for multiple sclerosis is experimentally 
induced autoimmune encephalomyelitis (EAE), which was accidently discovered by 
Louis Pasteur in 1893 as a complication in his search for an antirabies vaccine, where 
immunization of volunteers with dried brain preparations of rabies infected rabbits led 
to severe paralysis symptoms and incidence estimates reached from 1 per 3000 to 
35000 vaccinations for this complication [357]. Only in the 1930s it has been 
recognized by Rivers and coworkers that minor myelin proteins included in central 
nervous tissue preparations of virus infected encephalitis patients and not the virus per 
se transferred encephalitis like disease to non human primates [357].  
A demyelinating disease in genetically susceptible rodents can be induced with both 
major as well as minor protein components of the myelin sheath like proteolipid protein 
(PLP), myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) 
or their immunodominant epitopes emulsified in IFA or CFA. A surprising result came 
when one report clearly indicated induction of MOG induced EAE, in MOG deficient 
mice expressing a transgenic TCR specific for MOG 35-55, attributing it to cross 
reactivity to a neurofilament M peptide that shared essential TCR contact points leading 
to an autoimmune attack on the CNS [358]. Generally, pertussis toxin (PTX) is given 
as an additional environmental stimulus during EAE induction believed to enhance the 
breakdown of the blood brain barrier (BBB) initiating disease pathology, though an 
immunomodulatory role altering the immune response to CNS autoantigens has also 
been proposed [359,360]. Depending on the genetic background of the mice and the 
immunization protocol used, the disease course may vary and both acute forms of EAE 
and more chronic relapsing pathogenesis were described [361]. With regard to this 
thesis the most important model is the MBP peptide 89-101 induced EAE, which 
produces a chronic progressing and/or relapsing disease in B10.RIII mice starting seven 
to sixteen days after initial immunization with 250 µg myelin basic protein peptide 
emulsified in Mycobacterium tuberculosis H37RA strain containing CFA [362].  
EAE is classically considered a T cell mediated autoimmune model and similarly to 
CIA knock out mice for T cell associated costimulatory molecule CD28 are relatively 
protected from EAE induction and progression of the disease [363,364]. However, 
ICOS deficiency renders mice particularly sensitive to EAE and CD28 independent 
EAE induction has also been reported [278,365]. EAE has been perceived as a TH1 
type of disease and genetic ablation of INFγ or its receptors and neutralization of IFNγ 
promoted the disease in murine models [366,367,368]. Moreover, anti-TNFα treatment 
with antagonistic antibodies found protective in animal models of demyelination [369]. 
However, discordant results in human clinical trials with supplementation of IFNγ and 
neutralizing TNF agents, led to a rigorous scientific debate about the usefulness of EAE 
as a relevant animal model in humans [370,371]. Additional confusion in the literature 
arose from reports that clearly showed that genetic ablation of IL-12p35 did not 
abrogate clinical EAE even though IL-12 is considered a signature cytokine for TH1 T 
cell differentiation [372]. The discovery of a novel T cell subset termed TH17, due to 
production of IL-17a and initially derived by in vitro differentiation using IL-6 and 
TGFβ, provided novel clues for the understanding of EAE pathogenesis as these cells 
were shown to be critical for initiation of EAE elicited by T cell transfer [373,374,375]. 
The identification of the heterologous cytokine IL-23, a member of the IL-12 cytokine 
family, sharing the IL-12p40 subunit with the eponymous cytokine provided a key for 
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the understanding of the aforementioned discrepancies in CNS pathology during EAE 
development associated with IL-12 deficiency [376,377]. Paradoxically, therapeutic 
targeting of IL-17 with antagonistic antibodies as well as transgenic overexpression 
does not alter susceptibility to murine EAE dramatically, arguing for redundant roles of 
this cytokine in the disease process [378,379]. Instead, Codarri and colleagues proposed 
GM-CSF as a non-redundant cytokine mediating CNS pathology in the EAE model 
[380].  
Although, EAE is generally not considered to be an autoimmune model that is majorly 
governed by autoantibodies, a role for B cells in disease susceptibility has been 
suggested. In fact, EAE experiments by Janeway and others using B cell deficient mice 
first indicated a regulatory role for these cells in the disease process [381]. Additional 
circumstantial evidence for a role of B cells in MS stems from the fact that oligoclonal 
bands of immunoglobulins are a diagnostic criterium for MS in humans and transfer of 
anti-MOG serum has been shown to lead to an exacerbation of MOG induced EAE in 
mice [382]. Very recent experiments indicated B cell derived IL-6 as an important 
pathogenic player, by which B lymphocytes drive EAE pathogenesis [383]. 
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PRESENT INVESTIGATIONS 
PAPER I 
In this study we assessed the influence of the genetic background on the ability to 
detect the strongest previously described non-MHC loci for PIA. To do so we 
transferred congenic fragments containing three non-MHC QTL in rat experimental 
arthritis from the susceptible DA rat into the disease-resistant E3 strain. We found that 
a disease promoting, DA derived, congenic fragment containing the arthritis regulating 
Ncf1 gene did not break resistance in the E3 genetic background, but enhanced 
autoimmune B cell responses. The introgression of the disease promoting loci Pia5 and 
Pia7, also located on rat chromosome 4, ultimately broke the resistance and led to 
arthritis development in the E3 rat. To assess the genetic effect of the MHC, an E3 
derived MHC congenic strain was transferred into the susceptible DA background and 
various F(1) and F(2) hybrids were generated and monitored for arthritis susceptibility. 
Our results show that the E3 derived MHC locus introgressed onto DA background 
enhanced arthritis only when it interacted with E3 genes on a mixed background. We 
also assessed epigenetic effects using F1 hybrids using yin yang crosses. We found a 
small but significant effect on arthritis susceptibility in progeny of DA mothers, 
however since the effect was not transient over the course of the experiment, we 
concluded that epigenetic effects mediated by X chromosomes and mitochondria do not 
play a major role in PIA susceptibility in this setting. Similarly, we did not detect a 
major influence of the Y chromosome on the development of PIA, as male rats derived 
from our experimental cross showed almost identical arthritis. The findings in these 
congenic lines confirm the existence of 3 major QTLs that regulate the severity of 
arthritis and are sufficient to induce the transformation of a completely arthritis-
resistant rat strain into an arthritis-susceptible strain. This study also reveals a dramatic 
difference in the arthritis-regulatory potential of the rat MHC depending on genetic 




Precise definition of the pathways involved in disease pathogenesis posts a major 
obstacle for therapeutic intervention in common complex autoimmune diseases. 
Identification of genetic factors in model organisms holds significant promise for an 
increased understanding of disease pathology and thereby may aid rationale drug 
development. In the present study we aimed to utilize HS mice, a novel tool for genome 
wide mapping in rodents, in order to map CIA, the most frequently used animal model 
for RA in humans. We used mice derived from the Northport stock with genomic 
contributions from eight different mouse strains, and crossed them with the arthritis 
susceptible C57BL10/Q (BQ) strain. We selected H2-q homozygotes from the F2 
generation and further intercrossed them for an additional generation, to generate a 
large F3 population that could be used to study the genetic architecture of CIA. Overall, 
we immunized and phenotyped a cohort of 1764 mice for arthritis development. In 
order to gain maximum information of our collaborative effort, we additionally 
analyzed approximately 100 biochemical, metabolical and haematological phenotypes. 
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All mice were genotyped and for the bioinformatic analysis we used the HAPPY 
algorithm. We thereby, found 26 loci for CIA, of which 18 were novel. We fine 
mapped a number of previously described loci, with particular importance for the Cia2 
(C5) locus on murine chromosome 2 and the Fc gamma receptor locus (Fcgr) on 
chromosome 1. Our study outlines the usefulness of heterogeneous stock derived 
mouse cohorts for mapping of quantitative traits. We provided one of the most 
comprehensive genetic analyses of CIA, which serves as an excellent resource for 
further fine mapping of existing CIA loci. 
 
PAPER III 
In this study expanded our previous genome wide analysis in a HS derived mouse 
cohort, to also analyse QTLs controlling autoantibodies towards CII, ACPA and RF a 
hallmark of human RA. All antibody concentrations were measured by standard 
ELISA, and linkage analysis was performed using a linear regression based method. 
We thereby set out to identify loci controlling formation of anti-CII antibodies of 
different IgG isotypes (IgG1, IgG3) and antibodies to major CII epitopes (C1, J1, U1), 
which are also recognized in a subset of RA patients strengthening the role of CIA as a 
relevant animal model for RA. Additionally, we investigated the humoral immune 
response towards a citrullinated CII peptide (CitC1) and RF. Both ACPA and RF are 
part of the revised ACR and EULAR criteria to classify RA diagnosis in humans. We 
found that the anti-CII antibody-, ACPA- and RF responses were all controlled by 
distinct genes, with particular importance for the immunoglobulin heavy chain (IgvH) 
locus, the Fc gamma receptor (Fcgr) locus and the complement component 1 (C1q) 
locus. Our study demonstrated that not only anti-CII antibodies, but interestingly also 
ACPA and RF are associated with arthritis development in mice. We reported the to 
date most comprehensive genetic analysis of clinically relevant antibody response 
during CIA development using a HS derived cohort of mice. Our data indicates 
complex genetic control anti-CII antibodies of different isotypes, ACPA and RF, which 
are all governed by unique and few shared loci. Clearly, our results argue in favour of 
the idea that antibody specificity is also determined by non-MHC genes, with particular 
importance for the IgvH locus. In conclusion, our study demonstrates the potential of 




We have previously identified a locus (Cia21) on murine chromosome 3 that 
predominantly affects CIA severity in female mice. Gender differences in incidence of 
human autoimmune diseases such as MS and RA are well documented in the literature, 
whereas the aetiology of this phenomenon remains largely elusive. Therefore, we 
decided to systematically investigate the role of sexual dimorphism in a congenic strain 
harbouring the Cia21 locus. To isolate the underlying chromosomal region, we 
performed traditional congenic mapping down to a single gene congenic mouse line 
that revealed relative protection in T cell mediated models of autoimmunity exclusively 
in female mice. In order to sought out the influence of female gonadal hormones we 
used castrated mice, which showed a complete ablation of the protective effect of 
Cia21 on EAE susceptibility, arguing for a direct role of female sex hormones in 
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susceptibility to autoimmune disease in our model. Thereafter, we demonstrated that 
the costimulatory molecule CD2, which is located outside of the original congenic 
fragment, is differentially expressed in vivo in the thymus between congenic and wild 
type animals. We then carefully characterized of estrogen receptor related (ERR) 
binding sites encoded within the congenic fragment and indicated by previous 
chromatin immunoprecipitation experiments. Targeted resequencing revealed several 
SNPs between the B10.RIII and RIIIS/J derived congenic mouse strain that alter these 
transcription factor binding sites, one of which in fact led to an alteration of a oestrogen 
response element (ERE). With our study, we successfully positionally identified a 
region that controls genetic susceptibility to complex autoimmunity. Our study for the 
first time identifies CD2, a protein involved in T cell costimulation, as a risk factor for 
sexual dimorphism in joint and CNS tissue autoimmunity in mice. At last these results 
underscore the importance of transcription factor binding sites, enhancer and silencer 
elements that are not directly associated with a particular gene for the control of 




Infections with pathogens have long been suspected to initiate or perpetuate the 
autoimmune process in complex disease pathologies. So far, epidemiological studies 
aiming to associate human RA with a specific infection, proposing a certain infectious 
organism as an environmental trigger for the disease leading to breach of tolerance to 
self and subsequent autoimmunity, have been unsuccessful. We investigated this issue 
using the previously described partial advanced intercross between Eae3 and Eae2 
bicongenic mice, by which several sub QTLs of the Cia5 locus on murine chromosome 
3 have been identified; one of them (Cia22) affects disease severity during the late 
phase of CIA. We dissected the original Cia22 region using recombination assisted 
breeding protocols and found reduced CIA development in a 2.38 Mb RIIIS/J derived 
fragment encompassing the murine chitinase like gene locus. Moreover, this congenic 
showed a clear adjuvant specific protective effect on CAIA susceptibility, indicating 
distinct pathways by which bacterial and yeast derived adjuvant perpetuate chronic 
inflammation of the joints. Experiments using mice deficient in the Ncf1 gene, 
highlighted the importance of NOX2 derived ROS producing cells being critical for the 
arthritoprotective effect on CAIA development mediated by Cia22. By combining 
exome sequencing and gene expression analysis of closely related murine chitinase like 
genes, we identified the Chi3l3 (Ym1) gene as a likely candidate for Cia22, with its 
expression virtually absent in RIIIS/J derived congenic mice. Targeted resequencing of 
the promoter of Chi3l3 identified several candidate SNPs that may influence mRNA 
and subsequently protein expression by alteration of essential transcription factor or 
RNA polymerase binding sites. Overall, our study identified CHI3l3 as a novel 
adjuvant specific regulator of experimental arthritis in mice, thereby indicating a 
previously unrecognized immunomodulatory mechanism of pathogen derived pattern 
recognition molecules altering susceptibility to chronic inflammatory joint disease 
mediated by ROS producing granulocytic cells. It underscores the importance of 
careful characterization of inflammatory pathways involving different pattern 
recognition receptors that in turn may hold significant promise for future for therapeutic 
intervention in chronic inflammatory diseases. 
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CONCLUDING REMARKS 
With the work presented in this thesis, we investigated the genetic control of 
autoimmunity in experimental rodent models of RA and MS. Animal models that can 
be run under stable environmental conditions with potentially unlimited cohort size 
provide a unique opportunity to unravel genetic factors controlling the heritability of 
complex autoimmune traits. We examined the genetic effects of previously identified 
PIA QTLs in an otherwise resistant genetic background of the laboratory rat, thereby 
outlining the importance of genetic interactions for the susceptibility to experimental 
artritis. We secondly introduced HS mice as a novel tool for improved QTL mapping 
for CIA and the associated autoantibody response. Lastly, we identified Cd2 and 
Chi3l3 as novel candidate genes for the arthritis regulating QTLs Cia21 and Cia22 
respectively. Despite these apparent successes there are several open questions that yet 
remain unresolved as the hypothesis free, positional cloning of polymorphisms 
underlying autoimmune QTLs using either association studies in HS mice or locus 
based congenic dissection prove more difficult than initially anticipated.  
Unfortunately, our HS study using an inbred outbred rodent population did not yield 
conclusive results on the positional identification of previously implicated 
polymorphisms in candidate genes like Hc (C5). This may be explained by either an 
over estimation of genetic effect of a given mutation on a complex phenotype like 
arthritis, an underestimation of the complex interactions between a certain mutation and 
the genetic background with many different alleles segregating in our HS cohort or 
thirdly the low frequency of susceptibility allele. The introduction of affordable 
genotyping technology and the availability of large patient cohorts for autoimmune 
disease, which resulted in an explosion of data concerning the identification of genetic 
factors for common complex autoimmune disease involving chronic inflammation, 
authors argued against the necessity for gene identification in model systems. However, 
one should keep in mind that the GWAS approach faces problems and therefore 
enormous sample sizes for the identification of statistically significant polymorphisms 
are needed. In addition, these studies often yield the most significant hits in intergenic 
regions that are not associated with any particular gene or they identify a series of 
significantly associated SNPs that are in linkage disequilibrium and stretch over several 
genes. Thus, GWAS rarely provide mechanistic understanding of how a particular 
polymorphism invokes on a pathway that ultimately changes genetic susceptibility to a 
particular disease. We face a similar problem in our Cia21 and Cia22 project, but with 
the mouse genome being completely accessible to genomic manipulation it is 
theoretically possible to experimentally validate our candidate genes. Therefore, the 
dissection of the complex genetics of quantitative traits in model organisms will 
continue to aid our understanding of the genetic heritability of these traits in humans. It 
also underscores the importance for the continuous development of new animal models 
to accurately mimicking the disease to identify novel genes and pathways associated 
with complex autoimmunity in humans and ultimately improve therapeutic options for 
affected patients. 
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